- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT03659591
Triple Aim Psychotherapy: Aimed at Improving Patient Experience, Population Health, and Cost (TAP)
Triple Aim Psychotherapy: an RCT Comparing Cognitive Behaviour Therapy (CBT) to Adaptive Psychological Training (APT) - a Treatment Aimed at Improving Patient Experience, Population Health, and Cost-effectiveness
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Depression and anxiety are highly prevalent in the general population. Community mental health programs in publically-funded jurisdictions such as Canada often have relatively limited, fixed budgets in order to provide services, which can result in inadequate access to effective treatment for patients. Cognitive Behaviour Therapy (CBT) is a gold-standard psychotherapeutic treatment for depression and anxiety. In order to improve access to treatment, community mental healthcare settings often provide CBT in a group format for patients experiencing mild-to-moderate symptoms. However, typical protocols for delivering group CBT in a community setting nonetheless require a considerable investment of limited clinician time.
The question arises as to whether this is the most efficient and effective use of clinician time; in other words, per hour spent of clinician time, does this approach maximize the number of patients experiencing adequate and meaningful clinical improvement? The Institute for Healthcare Improvement (IHI) developed the Triple Aim, which is a framework describing an approach to optimizing health system performance by simultaneously pursuing three dimensions, namely improving the patient experience of care; improving the health of populations; and reducing the associated per capita costs of care. Studies of psychotherapy rarely pursue all three of these dimensions simultaneously. Efforts to achieve the best clinical outcome for an individual often lead to restrictive inclusionary/exclusionary criteria that sacrifice reaching the wider population; conversely, efforts to improve population health often prioritize composite overall clinical improvement across an entire group, even though the change experienced by many of the individuals in the population might not be clinically meaningful; focusing primarily on cost-effectiveness often sacrifices the individual's experience and/or the population's needs.
Adaptive Psychological Training (APT) is a group-based psychotherapy designed with all of the dimensions of the Triple Aim in mind simultaneously. In its development, APT drew heavily upon Mindfulness-Based Cognitive Therapy, an evidence-based psychotherapy that itself draws upon both evidence-based eastern psychotherapeutic practices and CBT, but APT also drew upon other evidence-based and evidence-supported psychotherapies including interpersonal and relational approaches, as well as meaning-focused psychoanalytic models. It also drew from psychology and neuroscience more broadly, as well as from learning theory and from practical clinical and operational experience. Inclusion/exclusion criteria, group size, number of sessions, in-session practice and learning, and between-session practice and learning were all adapted from the perspective of trying to achieve high quality outcomes for a broader population within more contained costs, and thereby increase access to quality care.
To-date, APT has already demonstrated positive outcomes in pilot research and in community clinical settings. The purpose of this specific study is to determine whether for a given population of patients experiencing mild-to-moderate symptoms of depression and/or anxiety, APT can facilitate meaningful change for more patients per time spent by clinicians than can CBT (the gold standard). The significance of this study includes its potential contribution to determining how best to deploy the limited resource of clinician time in a community setting in order to best help the most people.
Tipo de estudo
Inscrição (Antecipado)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Ontario
-
Burlington, Ontario, Canadá, L7S OA2
- Joseph Brant Hospital
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Treatment-seeking adults, interested and willing to participate in group psychotherapy
- Mild-to-moderate depressive (score of ≥10 and <20 on PHQ9) and/or anxious (score of ≥8 and <15 on GAD7) symptoms
- Ability to communicate, in written and spoken English
Exclusion Criteria:
- Severe depressive/anxious symptoms
- Patients where the primary clinical focus is active suicidality or harm-to-others, psychosis, mania, substance use, posttraumatic stress, or personality pathology such that it would interfere with group function
- Recent course(s) of the study psychotherapies
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Comparador Ativo: Cognitive Behaviour Therapy
10 week, manual-based group CBT treatment for depression and anxiety, followed by optional booster sessions
|
CBT will be delivered in group format, consisting of 10 weekly two-hour sessions, with 10 participants per group
Outros nomes:
|
Comparador Ativo: Adaptive Psychological Training
5 week, manual-based group APT treatment for depression and anxiety, followed by optional booster sessions
|
APT will be delivered in group format, consisting of 5 weekly two-hour sessions, with 20 participants per group
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Triple Aim Measure
Prazo: At 10 weeks; in a secondary fashion, this outcome will also be examined every two weeks across 6 months
|
Numerator: The number of patients achieving reliable recovery; denominator: clinician time spent in hours ('reliable recovery' is defined as scores below 'caseness' for both depression [<10 on Patient Health Questionnaire (PHQ-9)] and anxiety [<8 on Generalized Anxiety Disorder-7 (GAD-7)], with any change from above caseness to below caseness meeting the threshold of the Reliable Change Index)
|
At 10 weeks; in a secondary fashion, this outcome will also be examined every two weeks across 6 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Triple Aim Measure - recovery only
Prazo: At 10 weeks; in a secondary fashion, this outcome will also be examined every two weeks across 6 months
|
Triple Aim Composite Score (as above), but without the Reliable Change Index requirement
|
At 10 weeks; in a secondary fashion, this outcome will also be examined every two weeks across 6 months
|
Triple Aim Measure - improvement only
Prazo: At 10 weeks; in a secondary fashion, this outcome will also be examined every two weeks across 6 months
|
Triple Aim Composite Score (as above), but without the remission requirement
|
At 10 weeks; in a secondary fashion, this outcome will also be examined every two weeks across 6 months
|
Change from baseline - depressive symptoms
Prazo: Pre- (week 0) and repeated every two weeks across 6 months
|
Scale used to measure depressive symptoms is the Patient Health Questionnaire (PHQ-9); score ranges from 0-27, where higher values indicate more depressive symptoms (worse outcome)
|
Pre- (week 0) and repeated every two weeks across 6 months
|
Change from baseline - anxiety symptoms
Prazo: Pre- (week 0) and repeated every two weeks across 6 months
|
Scale used to measure anxiety symptoms is the Generalized Anxiety Disorder 7-item (GAD-7) Scale; score ranges from 0-21, where higher values indicate more anxiety symptoms (worse outcome)
|
Pre- (week 0) and repeated every two weeks across 6 months
|
Change from baseline - function
Prazo: Pre- (week 0) and repeated monthly across 6 months
|
Scale used to measure function is the World Health Organization Disability Assessment Schedule 2.0 - 12 item version (WHODAS 2.0 12-item); score ranges from 0-48, where higher values indicate lower functioning (worse outcome)
|
Pre- (week 0) and repeated monthly across 6 months
|
Change from baseline - mental wellbeing
Prazo: Pre- (week 0) and repeated monthly across 6 months
|
Scale used to measure mental wellbeing is the Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS); score ranges from 14-70, where higher values indicate greater mental wellbeing (better outcome)
|
Pre- (week 0) and repeated monthly across 6 months
|
Change from baseline - self-compassion
Prazo: Pre- (week 0) and repeated monthly across 6 months
|
Scale used to measure self-compassion is the Self-Compassion Scale - Short Form (SCS-SF); score ranges from 12-60, where higher values indicate greater self-compassion (better outcome)
|
Pre- (week 0) and repeated monthly across 6 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Steven Selchen, MD MSt FRCPC, Joseph Brant Hospital
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Antecipado)
Conclusão Primária (Antecipado)
Conclusão do estudo (Antecipado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 000-044-18
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Cognitive Behaviour Therapy
-
Pamukkale UniversityConcluído
-
University of PennsylvaniaRescindidoInfecção Recorrente por Clostridium DifficileEstados Unidos
-
Azienda Ospedaliera Universitaria Integrata VeronaConcluído
-
University of Roma La SapienzaConcluídoFalha no implante dentário | Mucosite OralItália
-
University of Applied Sciences and Arts of Southern...Vrije Universiteit Brussel; Universiteit Antwerpen; THIM - die internationale...Concluído
-
NeuroTronik Inc.DesconhecidoInsuficiência Cardíaca AgudaPanamá
-
CellMedX CorporationNutrasource Pharmaceutical and Nutraceutical Services, Inc.Concluído
-
Columbia UniversityRescindido
-
University of PennsylvaniaRescindidoInfecção Grave por Clostridium Difficile | Infecção Grave Complicada/Fulminante por Clostridium DifficileEstados Unidos
-
The Cleveland ClinicRecrutamentoEstrabismo | AmbliopiaEstados Unidos